Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to “Buy” at StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Down 3.3 %

Shares of AUPH stock traded down $0.32 during trading hours on Friday, reaching $9.37. 1,277,609 shares of the stock were exchanged, compared to its average volume of 1,607,037. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -62.46 and a beta of 1.41. Aurinia Pharmaceuticals has a 12-month low of $4.71 and a 12-month high of $10.67. The company’s 50-day moving average price is $7.99 and its 200-day moving average price is $6.71. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Insider Buying and Selling

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the transaction, the director now owns 13,356 shares in the company, valued at $112,591.08. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its stake in Aurinia Pharmaceuticals by 4,307.9% during the 3rd quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after buying an additional 535,301 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the third quarter valued at about $3,330,000. Stonepine Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at approximately $1,713,000. AQR Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at approximately $1,155,000. Finally, Barclays PLC boosted its stake in Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock worth $1,607,000 after purchasing an additional 143,072 shares in the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.